Notably, in one of the above-mentioned preclinical studies, the FOLFIRI combination reduced Notch1 expression in colon cancer cells, which could be a possible explanation underlying the lack of expected efficacy of adding a Notch inhibitor to this chemotherapeutics combination [556]. This evidence concerns the gene NOTCH1 and colonic neoplasm.